Skip to main content
Top
Published in: Abdominal Radiology 11/2018

01-11-2018

Quantitative dynamic contrast-enhanced MR imaging for differentiating benign, borderline, and malignant ovarian tumors

Authors: Hai-ming Li, Feng Feng, Jin-wei Qiang, Guo-fu Zhang, Shu-hui Zhao, Feng-hua Ma, Yong-ai Li, Wei-yong Gu

Published in: Abdominal Radiology | Issue 11/2018

Login to get access

Abstract

Purpose

This study aimed to investigate the diagnostic performance of quantitative DCE-MRI for characterizing ovarian tumors.

Methods

We prospectively assessed the differences of quantitative DCE-MRI parameters (Ktrans, kep, and ve) among 15 benign, 28 borderline, and 66 malignant ovarian tumors; and between type I (n = 28) and type II (n = 29) of epithelial ovarian carcinomas (EOCs). DCE-MRI data were analyzed using whole solid tumor volume region of interest (ROI) method, and quantitative parameters were calculated based on a modified Tofts model. The non-parametric Kruskal–Wallis test, Mann–Whitney U test, Pearson’s chi-square test, intraclass correlation coefficient (ICC), variance test, and receiver operating characteristic curves (ROC) were used for statistical analysis.

Results

The largest Ktrans and kep values were observed in ovarian malignant tumors, followed by borderline and benign tumors (all P < 0.001). Kep was the better parameter for differentiating benign tumors from borderline and malignant tumors, with a sensitivity of 89.3% and 95.5%, a specificity of 86.7% and 100%, an accuracy of 88.4% and 96.3%, and an area under the curve (AUC) of 0.94 and 0.992, respectively, whereas Ktrans was better for differentiating borderline from malignant tumors with a sensitivity of 60.7%, a specificity of 78.8%, an accuracy of 73.4%, and an AUC of 0.743. In addition, a combination with kep could further improve the sensitivity to 78.9%. The median Ktrans and kep values were significantly higher in type II than in type I EOCs.

Conclusion

DCE-MRI with volume quantification is a technically feasible method, and can be used for the differentiation of ovarian tumors and for discriminating between type I and type II EOCs.
Literature
1.
go back to reference Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumours of female reproductive organs. Lyon: IARC Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumours of female reproductive organs. Lyon: IARC
2.
go back to reference Morgan RJ, Armstrong DK, Alvarez RD, et al. (2016) Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14:1134–1163CrossRef Morgan RJ, Armstrong DK, Alvarez RD, et al. (2016) Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14:1134–1163CrossRef
3.
go back to reference Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol 34:433–443CrossRef Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol 34:433–443CrossRef
4.
go back to reference Satoh T, Hatae M, Watanabe Y, et al. (2010) Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol 28:1727–1732CrossRef Satoh T, Hatae M, Watanabe Y, et al. (2010) Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol 28:1727–1732CrossRef
5.
go back to reference Song T, Choi CH, Kim HJ, et al. (2011) Accuracy of frozen section diagnosis of borderline ovarian tumors. Gynecol Oncol 122:127–131CrossRef Song T, Choi CH, Kim HJ, et al. (2011) Accuracy of frozen section diagnosis of borderline ovarian tumors. Gynecol Oncol 122:127–131CrossRef
6.
go back to reference Bazot M, Nassar-Slaba J, Thomassin-Naggara I, et al. (2006) MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors: correlation with final histology. Eur Radiol 16:2687–2699CrossRef Bazot M, Nassar-Slaba J, Thomassin-Naggara I, et al. (2006) MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors: correlation with final histology. Eur Radiol 16:2687–2699CrossRef
7.
go back to reference Vargas HA, Barrett T, Sala E (2013) MRI of ovarian masses. J Magn Reson Imaging 37:265–281CrossRef Vargas HA, Barrett T, Sala E (2013) MRI of ovarian masses. J Magn Reson Imaging 37:265–281CrossRef
8.
go back to reference García-Figueiras R, Padhani AR, Beer AJ, et al. (2015) Imaging of tumor angiogenesis for radiologists—Part 2: Clinical utility. Curr Probl Diagn Radiol 44(5):425–436CrossRef García-Figueiras R, Padhani AR, Beer AJ, et al. (2015) Imaging of tumor angiogenesis for radiologists—Part 2: Clinical utility. Curr Probl Diagn Radiol 44(5):425–436CrossRef
9.
go back to reference Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT (2007) Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 8(1):63–74CrossRef Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT (2007) Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 8(1):63–74CrossRef
10.
go back to reference O’Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC (2012) Dynamic contrast-enhanced MR in clinical trials of antivascular therapies. Nat Rev Clin Oncol 9(3):167–177CrossRef O’Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC (2012) Dynamic contrast-enhanced MR in clinical trials of antivascular therapies. Nat Rev Clin Oncol 9(3):167–177CrossRef
11.
go back to reference Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97(3):172–187CrossRef Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97(3):172–187CrossRef
12.
go back to reference Kazerooni AF, Malek M, Haghighatkhah H, et al. (2017) Semiquantitative dynamic contrast-enhanced MRI for accurate classification of complex adnexal masses. J Magn Reson Imaging 45(2):418–427CrossRef Kazerooni AF, Malek M, Haghighatkhah H, et al. (2017) Semiquantitative dynamic contrast-enhanced MRI for accurate classification of complex adnexal masses. J Magn Reson Imaging 45(2):418–427CrossRef
14.
go back to reference Thomassin-Naggara I, Bazot M, Daraï E, et al. (2008) Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology 248(1):148–159CrossRef Thomassin-Naggara I, Bazot M, Daraï E, et al. (2008) Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology 248(1):148–159CrossRef
15.
go back to reference Thomassin-Naggara I, Daraï E, Cuenod CA, et al. (2008) Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J Magn Reson Imaging 28(1):111–120CrossRef Thomassin-Naggara I, Daraï E, Cuenod CA, et al. (2008) Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J Magn Reson Imaging 28(1):111–120CrossRef
17.
go back to reference Dilks P, Narayanan P, Reznek R, Sahdev A, Rockall A (2010) Can quantitative dynamic contrast-enhanced MRI independently characterize an ovarian mass? Eur Radiol 20(9):2176–2183CrossRef Dilks P, Narayanan P, Reznek R, Sahdev A, Rockall A (2010) Can quantitative dynamic contrast-enhanced MRI independently characterize an ovarian mass? Eur Radiol 20(9):2176–2183CrossRef
18.
go back to reference Bernardin L, Dilks P, Liyanage S, et al. (2012) Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol 22(4):880–890CrossRef Bernardin L, Dilks P, Liyanage S, et al. (2012) Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol 22(4):880–890CrossRef
19.
go back to reference Patel N, Harris AL, Gleeson FV, Vallis KA (2012) Clinical imaging of tumor angiogenesis. Future Oncol 8(11):1443–1459CrossRef Patel N, Harris AL, Gleeson FV, Vallis KA (2012) Clinical imaging of tumor angiogenesis. Future Oncol 8(11):1443–1459CrossRef
20.
go back to reference Carter JS, Koopmeiners JS, Kuehn-Hajder JE, et al. (2013) Quantitative multiparametric MRI of ovarian cancer. J Magn Reson Imaging 38(6):1501–1509CrossRef Carter JS, Koopmeiners JS, Kuehn-Hajder JE, et al. (2013) Quantitative multiparametric MRI of ovarian cancer. J Magn Reson Imaging 38(6):1501–1509CrossRef
21.
go back to reference Priest AN, Gill AB, Kataoka M, et al. (2010) Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med 63(4):1044–1049CrossRef Priest AN, Gill AB, Kataoka M, et al. (2010) Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med 63(4):1044–1049CrossRef
22.
go back to reference Sala E, Kataoka MY, Priest AN, et al. (2012) Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology 263(1):149–159CrossRef Sala E, Kataoka MY, Priest AN, et al. (2012) Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology 263(1):149–159CrossRef
23.
go back to reference Thomassin-Naggara I, Balvay D, Aubert E, et al. (2012) Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study. Eur Radiol 22(4):738–745CrossRef Thomassin-Naggara I, Balvay D, Aubert E, et al. (2012) Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study. Eur Radiol 22(4):738–745CrossRef
24.
go back to reference Thomassin-Naggara I, Soualhi N, Balvay D, Darai E, Cuenod CA (2017) Quantifying tumor vascular heterogeneity with DCE-MRI in complex adnexal massed: a preliminary study. J Magn Resson Imaging 46(6):1776–1785CrossRef Thomassin-Naggara I, Soualhi N, Balvay D, Darai E, Cuenod CA (2017) Quantifying tumor vascular heterogeneity with DCE-MRI in complex adnexal massed: a preliminary study. J Magn Resson Imaging 46(6):1776–1785CrossRef
26.
go back to reference García-Figueiras R, Padhani AR, Beer AJ, et al. (2015) Imaging of tumor angiogenesis for radiologists—Part 1: biological and technical basis. Curr Probl Diagn Radiol 44(5):407–424CrossRef García-Figueiras R, Padhani AR, Beer AJ, et al. (2015) Imaging of tumor angiogenesis for radiologists—Part 1: biological and technical basis. Curr Probl Diagn Radiol 44(5):407–424CrossRef
27.
go back to reference Venkatasubramanian R, Arenas RB, Henson MA, Forbes NS (2010) Mechanistic modelling of dynamic MRI data predicts that tumor heterogeneity decreases therapeutic response. Br J Cancer 103(4):486–497CrossRef Venkatasubramanian R, Arenas RB, Henson MA, Forbes NS (2010) Mechanistic modelling of dynamic MRI data predicts that tumor heterogeneity decreases therapeutic response. Br J Cancer 103(4):486–497CrossRef
28.
go back to reference Liu C, Wang K, Chan Q, et al. (2016) Intravoxel incoherent motion MR imaging for breast lesions: comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging. Eur Radiol 26(11):3888–3898CrossRef Liu C, Wang K, Chan Q, et al. (2016) Intravoxel incoherent motion MR imaging for breast lesions: comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging. Eur Radiol 26(11):3888–3898CrossRef
29.
go back to reference Yuan M, Zhang YD, Zhu C, et al. (2016) Comparison of intravoxel incoherent motion diffusion-weighted MR imaging with dynamic contrast-enhanced MRI for differentiating lung cancer from benign solitary pulmonary lesions. J Magn Reson Imaging 43(3):669–679CrossRef Yuan M, Zhang YD, Zhu C, et al. (2016) Comparison of intravoxel incoherent motion diffusion-weighted MR imaging with dynamic contrast-enhanced MRI for differentiating lung cancer from benign solitary pulmonary lesions. J Magn Reson Imaging 43(3):669–679CrossRef
30.
go back to reference Xian J, Du H, Wang X, et al. (2014) Feasibility and value of quantitative dynamic contrast enhancement MR imaging in the evaluation of sinonasal tumors. Chin Med J (Engl) 127(12):2259–2264 Xian J, Du H, Wang X, et al. (2014) Feasibility and value of quantitative dynamic contrast enhancement MR imaging in the evaluation of sinonasal tumors. Chin Med J (Engl) 127(12):2259–2264
31.
go back to reference Shin JK, Kim JY (2017) Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: associations between quantitative MR parameters and Ki-67 proliferation status. J Magn Reson Imaging 45(1):94–102CrossRef Shin JK, Kim JY (2017) Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: associations between quantitative MR parameters and Ki-67 proliferation status. J Magn Reson Imaging 45(1):94–102CrossRef
32.
go back to reference Zhang N, Zhang L, Qiu B, et al. (2012) Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas. J Magn Reson Imaging 36(2):355–363CrossRef Zhang N, Zhang L, Qiu B, et al. (2012) Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas. J Magn Reson Imaging 36(2):355–363CrossRef
33.
go back to reference Mitchell CL, O’Connor JP, Jackson A, et al. (2010) Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol 21(10):1982–1989CrossRef Mitchell CL, O’Connor JP, Jackson A, et al. (2010) Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol 21(10):1982–1989CrossRef
34.
go back to reference Szubert S, Moszynski R, Michalak S, et al. (2016) The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors. Microvasc Res 107:91–96CrossRef Szubert S, Moszynski R, Michalak S, et al. (2016) The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors. Microvasc Res 107:91–96CrossRef
35.
go back to reference Thukral A, Thomasson DM, Chow CK, et al. (2007) Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 244(3):727–735CrossRef Thukral A, Thomasson DM, Chow CK, et al. (2007) Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 244(3):727–735CrossRef
36.
go back to reference Inven M, Reerink O, Philippens ME (2015) Dynamic contrast MR imaging for rectal cancer response assessment after neo-adjuvant chemotherapy. J Magn Reson Imaging 41(6):1646–1653CrossRef Inven M, Reerink O, Philippens ME (2015) Dynamic contrast MR imaging for rectal cancer response assessment after neo-adjuvant chemotherapy. J Magn Reson Imaging 41(6):1646–1653CrossRef
37.
go back to reference Sahani DV, Jiang T, Hayano K, et al. (2013) Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol 6:51CrossRef Sahani DV, Jiang T, Hayano K, et al. (2013) Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol 6:51CrossRef
38.
go back to reference Yang J, Kim JH, Im GH, et al. (2011) Evaluation of antiangiogenic effects of a new synthetic candidate drug KR-31831 on xenografted ovarian carcinoma using dynamic contrast enhanced MRI. Korean J Radiol 12(5):602–610CrossRef Yang J, Kim JH, Im GH, et al. (2011) Evaluation of antiangiogenic effects of a new synthetic candidate drug KR-31831 on xenografted ovarian carcinoma using dynamic contrast enhanced MRI. Korean J Radiol 12(5):602–610CrossRef
39.
go back to reference Li X, Cai Y, Moloney B, et al. (2016) Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling. J Magn Reson 269:104–112CrossRef Li X, Cai Y, Moloney B, et al. (2016) Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling. J Magn Reson 269:104–112CrossRef
40.
go back to reference Yeo DM, Oh SN, Jung CK, et al. (2015) Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: preliminary results. J Magn Reson Imaging 41(2):474–480CrossRef Yeo DM, Oh SN, Jung CK, et al. (2015) Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: preliminary results. J Magn Reson Imaging 41(2):474–480CrossRef
41.
go back to reference Yi B, Kang DK, Yoon D, et al. (2014) Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients? Eur Radiol 24(5):1089–1096CrossRef Yi B, Kang DK, Yoon D, et al. (2014) Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients? Eur Radiol 24(5):1089–1096CrossRef
42.
go back to reference Jackson A, O’Connor JP, Parker GJ, Jayson GC (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13(12):3449–3459CrossRef Jackson A, O’Connor JP, Parker GJ, Jayson GC (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13(12):3449–3459CrossRef
Metadata
Title
Quantitative dynamic contrast-enhanced MR imaging for differentiating benign, borderline, and malignant ovarian tumors
Authors
Hai-ming Li
Feng Feng
Jin-wei Qiang
Guo-fu Zhang
Shu-hui Zhao
Feng-hua Ma
Yong-ai Li
Wei-yong Gu
Publication date
01-11-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 11/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-018-1569-1

Other articles of this Issue 11/2018

Abdominal Radiology 11/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.